Efgartigimod for New-onset Generalized Myasthenia Gravis
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- argenx · Industry
This trial is looking for adults who have recently been diagnosed with generalized myasthenia gravis (gMG). Participants will receive treatment with efgartigimod PH20 SC over a period of about 51 weeks.
You may be able to join if
- I am at least 18 years old.
- I have been diagnosed with gMG of MGFA class II, III, or IV.
- I have a positive AChR antibody test.
- I have not been treated for gMG before or have used AChEI.
- I had the first signs of gMG less than 1 year ago.
- I have an MG-ADL score of 5 or more.
You may not be able to join if
- I have gMG diagnosed as MGFA class I or V.
- I had a thymectomy before screening, except for a nonmalignant thymoma.
- I have used any systemic corticosteroid therapy for gMG.
- I have used any nonsteroidal immunosuppressive therapy for gMG.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.
Loading trial locations…